SPOTLIGHT: Rituxan data encourages researchers

Genentech and Biogen Idec say that the Phase II data for Rituxan as a therapy for multiple sclerosis exceeded their expectations. "Showing a significant benefit at 24 weeks in this small Phase II trial supports our hypothesis that selective B-cell targeted therapy may play an important role in the treatment of MS," said Genentech senior VP Hal Barron MD. Report

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.